New drug duo aims to control lymphoma without chemo

NCT ID NCT06263491

Recruiting now Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial is testing whether a combination of two drugs, pirtobrutinib and rituximab, can help people with untreated low or intermediate risk mantle cell lymphoma achieve long-term remission without chemotherapy. The study will enroll 50 adults who have not received prior treatment. Researchers will monitor safety and how well the cancer responds.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pirtobrutinib and rituximab
What this could lead to: If successful, this could offer a chemotherapy-free option that keeps mantle cell lymphoma under long-term control for low and intermediate risk patients.
What could go wrong: This is an early Phase 2 trial with only 50 participants, so results may not apply to all patients. Side effects from the drugs are possible, and long-term remission is not guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mantle cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MANTLE CELL LYMPHOMA

Contacts and locations

Locations

MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.